CVSC Cardiovascular Sciences Inc (CE)

Cardiovascular Sciences, Inc. (PINKSHEETS: CVSC) proudly announces their new retail website, www.Rejuven8online, is live and establishes the Company�s entrance and claim in the retail arena. This enables Cardiovascular Sciences, Inc. to introduce its nutritional flagship product, Rejuven8 �. Rejuven8 � is the Company�s premium antioxidant, anti-aging cell renewal nutritional supplement. The formula�s high potency and broad variety of natural components assure a strong claim in the burgeoning $6 billion nutritional supplement market. No other nutritional product currently available offers an overall advantage over Rejuven8 �, even at several times the price. Besides the very complete list of antioxidant vitamins and minerals, the formula contains extracts of eight fruits and plants, all known to have the highest content of natural antioxidants. �We are quite excited!� exclaims Cardiovascular Sciences� CEO, Dr. Larry Hooper. �Our premarketing experience with this product leads us to believe we have not just a winning entry with Rejuven8 �, but a very effective entry. This is not just another vitamin product. We have taken the extra time in the development process to insure that this is a potent weapon in the preventive healthcare arsenal.� Rejuven8 � is currently available only at the Company�s new website, www.Rejuven8online.com. However, several regional and national level distributor groups have expressed strong interest in making the product available. On this website, a few very select and complementary quality health related products are also offered. The company suggests that you also visit their corporate website, www.cvsciences.org, to obtain a promotional code good for an extra discount on any order at www.Rejuven8online.com. About Cardiovascular Sciences: Cardiovascular Sciences, Inc. is a medical device company with a primary focus of developing a novel technology platform that addresses problems of post-surgical adhesions. Adhesions and their complications are significant problems worldwide for a broad range of specialists, including general and cardiothoracic, orthopedic, plastic, ophthalmologic and otolaryngology specialists to name a few. In addition, the veterinary field has tremendous need for a product that can prevent similar problems in a variety of animals. The Company's unique materials and processes promise a more cost-effective and more capable means to deal with a problem, devastating to so many. Sponsored research at UCF and previously at other institutions indicate that the Company is on the right path, progressing well. In addition to anti-adhesion technology, the Company owns technology in other areas, yielding a diversified portfolio with projects in various stages of development. One of these is represented by the company�s antioxidant cell renewal formula, Rejuven8 � and a very select line of complementary health related offerings. Forward-looking statements here are made pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties. Actual results could differ from those discussed. This material is information only and not an offer or solicitation to buy or sell the securities.